Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster "Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)" on May 30 at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, taking place in Chicago, Illinois.

APR-1051 is an orally bioavailable, potent, and selective small molecule WEE1 inhibitor with in vivo anti-tumor activity in several cancer models. It exhibits low off-target inhibition of PLK kinases (PLK1, PLK2, PLK3), a property that differentiates it from prior WEE1 inhibitors and may contribute to an improved safety profile. ACESOT-1051 is the ongoing first-in-human Phase 1 study evaluating once-daily APR-1051 in advanced solid tumors harboring cancer-associated gene alterations.